Subsequent primary malignancies after diffuse large B‐cell lymphoma in the modern treatment era

Summary With the addition of rituximab and other treatment advances, survival after diffuse large B‐cell lymphoma (DLBCL) has improved, but subsequent primary malignancies (SPMs) have emerged as an important challenge for DLBCL survivorship. We calculated standardized incidence ratios (SIRs) and 95%...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of haematology 2017-07, Vol.178 (1), p.72-80
Hauptverfasser:	Tao, Li, Clarke, Christina A., Rosenberg, Aaron S., Advani, Ranjana H., Jonas, Brian A., Flowers, Christopher R., Keegan, Theresa H. M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute myeloid leukemia Adolescent Adult Aged Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use B-cell lymphoma California - epidemiology cancer diffuse large B‐cell lymphoma Female Follow-Up Studies Health risk assessment Hematology Humans Incidence Leukemia Leukemia, Myeloid, Acute - chemically induced Leukemia, Myeloid, Acute - epidemiology Lymphocytes B Lymphoma Lymphoma, Large B-Cell, Diffuse - drug therapy Lymphoma, Large B-Cell, Diffuse - epidemiology Male Melanoma Melanoma - chemically induced Melanoma - epidemiology Middle Aged Monoclonal antibodies Neoplasms, Second Primary - chemically induced Neoplasms, Second Primary - epidemiology Registries Rituximab Rituximab - adverse effects Rituximab - therapeutic use second primary malignancy Survival Targeted cancer therapy Thyroid cancer Thyroid Neoplasms - chemically induced Thyroid Neoplasms - epidemiology Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!